GAP PBC Bio-Hermes Program (Bio-Hermes) 

Recruitment and screening of appropriate participants for Alzheimer’s and other CNS clinical trials are the largest contributors to the high cost and long duration of these trials.  GAP PBC is developing a rigorous “pre-screening” data analytics program that will be deployed in future clinical trials, saving substantial time and tens of millions of dollars in the execution of future trials. To hone its biomarker strategy and optimize AI derived algorithms for trial design and characterizing trial populations, GAP PBC is initiating its own clinical study to organize the first systemic, well-characterized sampling and data collection effort focused on blood-based and digital biomarkers for this purpose.